These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21651401)

  • 21. Difficult-to-control hypertension: effects of olmesartan-based combination therapies.
    de la Sierra A
    J Hypertens; 2013 Mar; 31 Suppl 1():S1-2. PubMed ID: 23389082
    [No Abstract]   [Full Text] [Related]  

  • 22. Olmesartan for the prevention or delay of diabetic nephropathy: some considerations.
    Catalá-López F; Martín-Serrano G; Maciá MA; Montero D
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):678-9; author reply 679-80. PubMed ID: 22608016
    [No Abstract]   [Full Text] [Related]  

  • 23. [Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].
    Halimi S
    Presse Med; 2005 Oct; 34(18):1300-2. PubMed ID: 16269993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
    Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
    Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection.
    de la Sierra A; Volpe M
    J Hypertens; 2013 Mar; 31 Suppl 1():S13-7. PubMed ID: 23389083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Aug; 147(31-32):43. PubMed ID: 16128197
    [No Abstract]   [Full Text] [Related]  

  • 29. Olmesartan, migraine, and blood pressure.
    Iwasaki Y; Ikeda K
    Headache; 2006 Sep; 46(8):1309. PubMed ID: 16942482
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of olmesartan on blood pressure in patients with hypertension: specification on causality.
    Kawada T
    J Hum Hypertens; 2015 Jan; 29(1):69-70. PubMed ID: 24451269
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
    Ruilope L; Izzo J; Haller H; Waeber B; Oparil S; Weber M; Bakris G; Sowers J
    J Clin Hypertens (Greenwich); 2010 Jun; 12(6):422-30. PubMed ID: 20591087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Administration time difference of candesartin effect on albuminuria in type 2 diabetic patients.
    Shimizu H; Uehara Y; Ohsaki A; Okada S; Mori M
    Hypertens Res; 2009 Jun; 32(6):527-8. PubMed ID: 19373237
    [No Abstract]   [Full Text] [Related]  

  • 33. [Series: Clinical study from Japan and its reflections; Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)].
    Imai E
    Nihon Naika Gakkai Zasshi; 2011 Nov; 100(11):3386-92. PubMed ID: 22250438
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO; Coll JR; Tran ZV; Schrier RW
    Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
    Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).
    ; Uzu T; Sawaguchi M; Maegawa H; Kashiwagi A
    Hypertens Res; 2008 Jun; 31(6):1171-6. PubMed ID: 18716365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "ROADMAP" controversies.
    Cohen DL; Townsend RR
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):628. PubMed ID: 21806774
    [No Abstract]   [Full Text] [Related]  

  • 38. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
    Uchida J; Machida Y; Iwai T; Iguchi T; Kamada Y; Naganuma T; Kumada N; Kim T; Kawashima H; Nakatani T
    J Nephrol; 2011; 24(4):515-21. PubMed ID: 21240871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
    Hayashi K
    Hypertens Res; 2011 Aug; 34(8):910-2. PubMed ID: 21753772
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients.
    Scholze J; Schaefer A; Kreutz R
    Expert Opin Drug Saf; 2011 Mar; 10(2):185-96. PubMed ID: 21254872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.